FindTrial
Sign In

A prospective, real-world clinical study on the conversion of tenofovir disoproxil fumarate to propofol in the treatment of chronic hepatitis B

A prospective, real-world clinical study on the conversion of tenofovir disoproxil fumarate to propofol in the treatment of chronic hepatitis B

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038198
Enrollment
Unknown
Registered
2020-09-13
Start date
2020-12-01
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver disease

Interventions

Chronic hepatitis B patients being treated with TDF:Propofol fumarate tenofovir

Sponsors

The Fifth Affiliated Hospital of Sun Yat-Sen University, Infectious Disease Prevention and Control Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria (only when all the following criteria are met can they be included) : (1) Chronic hepatitis B patients treated with TDF; (2) Aged >= 18 years; (3) Be willing to sign the informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria (subjects are excluded from the study if they meet any of the following criteria): (1) Allergic to TAF or active ingredients; (2) Pregnant and lactating women; (3) Diagnosis of HCC within 3 months prior to enrollment; (4) Life expectancy less than 1 year; (5) Other researchers think it is not suitable to be included in this study.

Design outcomes

Primary

MeasureTime frame
Bone mineral density;Renal tubular function;Glomerular filtration rate;—

Countries

China

Contacts

Public ContactJinyu Xia

The Fifth Affiliated Hospital of Sun Yat-Sen Universit

xiajinyu@mail.sysu.edu.cn+86 13823078064

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026